MYC-MEDIATED APOPTOSIS REQUIRES WILD-TYPE P53 IN A MANNER INDEPENDENT OF CELL-CYCLE ARREST AND THE ABILITY OF P53 TO INDUCE P21(WAF1/CIP1)

被引:526
作者
WAGNER, AJ
KOKONTIS, JM
HAY, N
机构
[1] UNIV CHICAGO, DEPT PHARMACOL & PHYSIOL SCI, CHICAGO, IL 60637 USA
[2] UNIV CHICAGO, DEPT BIOCHEM & MOLEC BIOL, CHICAGO, IL 60637 USA
[3] UNIV CHICAGO, BEN MARY INST, CHICAGO, IL 60637 USA
关键词
ONCOGENE; TUMOR SUPPRESSOR; PROGRAMMED CELL DEATH;
D O I
10.1101/gad.8.23.2817
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Deregulated expression of the c-myc proto-oncogene can lead to apoptosis under certain physiological conditions. By introducing a conditionally active Myc allele into primary embryo fibroblasts null for p53, and into fibroblasts without endogenous p53 expression but ectopically expressing a temperature-sensitive p53 allele, we show that expression of wild-type p53 is required for susceptibility to Myc-mediated apoptosis. Although ectopic expression of wild-type p53 blocked cells in the G(1) phase of the cell cycle, G(1) arrest by isoleucine starvation, in a manner independent of p53, did not confer susceptibility to apoptosis. Thus, growth arrest per se is not sufficient to induce Myc-mediated apoptosis; instead, a property intrinsic to p53 is specifically required. Moreover, apoptosis did not require induction of p53 target proteins, including the cyclin-dependent kinase inhibitor p21(waf1/cip1). Therefore, the role of p53 in apoptosis may be distinct from its role in cell cycle arrest.
引用
收藏
页码:2817 / 2830
页数:14
相关论文
共 102 条
[41]  
HARVEY M, 1993, ONCOGENE, V8, P2457
[42]   NOVEL ZINC FINGER GENE IMPLICATED AS MYC COLLABORATOR BY RETROVIRALLY ACCELERATED LYMPHOMAGENESIS IN E-MU-MYC TRANSGENIC MICE [J].
HAUPT, Y ;
ALEXANDER, WS ;
BARRI, G ;
KLINKEN, SP ;
ADAMS, JM .
CELL, 1991, 65 (05) :753-763
[43]   P53 MUTATIONS IN HUMAN CANCERS [J].
HOLLSTEIN, M ;
SIDRANSKY, D ;
VOGELSTEIN, B ;
HARRIS, CC .
SCIENCE, 1991, 253 (5015) :49-53
[44]   DIFFERENTIAL MODULATION OF CYCLIN GENE-EXPRESSION BY MYC [J].
JANSENDURR, P ;
MEICHLE, A ;
STEINER, P ;
PAGANO, M ;
FINKE, K ;
BOTZ, J ;
WESSBECHER, J ;
DRAETTA, G ;
EILERS, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (08) :3685-3689
[45]   GROWTH SUPPRESSION OF FRIEND VIRUS-TRANSFORMED ERYTHROLEUKEMIA-CELLS BY P53 PROTEIN IS ACCOMPANIED BY HEMOGLOBIN PRODUCTION AND IS SENSITIVE TO ERYTHROPOIETIN [J].
JOHNSON, P ;
CHUNG, S ;
BENCHIMOL, S .
MOLECULAR AND CELLULAR BIOLOGY, 1993, 13 (03) :1456-1463
[46]  
JUVEN T, 1993, ONCOGENE, V8, P3411
[47]   A MAMMALIAN-CELL CYCLE CHECKPOINT PATHWAY UTILIZING P53 AND GADD45 IS DEFECTIVE IN ATAXIA-TELANGIECTASIA [J].
KASTAN, MB ;
ZHAN, QM ;
ELDEIRY, WS ;
CARRIER, F ;
JACKS, T ;
WALSH, WV ;
PLUNKETT, BS ;
VOGELSTEIN, B ;
FORNACE, AJ .
CELL, 1992, 71 (04) :587-597
[48]   FUNCTION OF THE C-MYC ONCOPROTEIN [J].
KATO, GJ ;
DANG, CV .
FASEB JOURNAL, 1992, 6 (12) :3065-3072
[49]   AN AMINO-TERMINAL C-MYC DOMAIN REQUIRED FOR NEOPLASTIC TRANSFORMATION ACTIVATES TRANSCRIPTION [J].
KATO, GJ ;
BARRETT, J ;
VILLAGARCIA, M ;
DANG, CV .
MOLECULAR AND CELLULAR BIOLOGY, 1990, 10 (11) :5914-5920
[50]   REDUCTION OF P53 GENE DOSAGE DOES NOT INCREASE INITIATION OR PROMOTION BUT ENHANCES MALIGNANT PROGRESSION OF CHEMICALLY-INDUCED SKIN TUMORS [J].
KEMP, CJ ;
DONEHOWER, LA ;
BRADLEY, A ;
BALMAIN, A .
CELL, 1993, 74 (05) :813-822